Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7269162 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO7269162 | EXPERIMENTAL | Participants will receive daily doses of RO7269162 for up to 72 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive daily doses of placebo for up to 72 weeks. |
| Name | Type | Description |
|---|---|---|
| RO7269162 | DRUG | Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks. |
| Placebo | DRUG | Participants will receive daily doses of placebo for up to 72 weeks. |
Inclusion Criteria: * Body Mass Index (BMI) between 18 to 35 kg/m\^2 inclusive at screening * Participants must be either cognitively unimpaired or with a diagnosis of MCI due to AD, according to the National Institute on Aging - Alzheimer's Association (NIA - AA) research framework * Clinical Deme...
Top 20 of 24 competitors
RO7269162 is an investigational small molecule being developed for Alzheimer's Disease. It is currently being studied in participants at risk for or at the prodromal stage of Alzheimer's Disease, meaning those who may be in the early or pre-symptomatic phases of the condition.
RO7269162 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting a Phase 2 clinical trial to evaluate the safety and biomarker effects of this investigational drug in Alzheimer's Disease.
RO7269162 is in Phase 2 of clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in Alzheimer's Disease.
RO7269162 is being studied in a Phase 2 trial with the identifier NCT06402838. This trial is active but not recruiting participants and has an enrollment of 256. It is a randomized, double-blind, placebo-controlled study evaluating safety and biomarker effects in Alzheimer's Disease.
RO7269162 is the primary name for this investigational drug. No alternative names have been associated with it in the available information, so it is not known to be the same as any other drug.